Loading
Atea Pharmaceuticals, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 17 Jan 2025.
Atea Pharmaceuticals, Inc.: what insiders have been doing
Every trade that managers of Atea Pharmaceuticals, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. In the past year (18 October 2025 to 18 October 2026), 13 filings came from 12 insiders.
Not one of the filings records a straightforward purchase or sale on the market. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
With 13 filings in twelve months, the company is quieter than the median of 19 filings across the 5,814 companies we follow on the same exchange. Over the whole record (from 2021), the tally stands at 2 purchases and 6 sales.
There has been no open-market purchase by an insider of Atea Pharmaceuticals, Inc. for at least a year. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. Section 16 rules allow two business days to file each Form 4.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
45
Thresholds
n/a
Buy Volume
€137,885
2 ops. · all time
Sell Volume
€1M
6 ops. · all time
Who traded when
BuySaleFranklin M. Berger2 buys1 sale
Since the insiders bought
- +6.2%Entry US$3.24 · Close at T+365 US$3.44
- -49.5%Entry US$9.13 · Close at T+365 US$4.61
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 24,045 of 24,148 companies
4.9
score / 100
Value5
Quality4
FCF yld-38%
Earn yld-46%
EV/EBITDA·
ROE-58%
Gross mgn·
Net mgn-52%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$4.98
Analyst consensus
3 analysts1.67/5
US$7.00Target US$9.42(+89%)US$11.25
Income statement
RevenueUS$302.5M
EBITDA-US$180.5M-60% margin
Net income-US$158.3M0.0% margin
Valuation
PER (forward)-3.4x
P/Book2.0x
Beta0.39
Balance sheet & cash
Market capUS$399.4M
Total debtUS$843k
Free Cash Flow-US$132M
Debt / Equity0%
Profitability & ownership
ROE-58.1%
ROA-36.7%
% insiders13.4%
% institutions79.2%
Last declaration on 23 June 2026
Declarations45 total
29,600 sharesCommon StockSEC:0001193125-26-279720:0
29,600 sharesCommon StockSEC:0001193125-26-279718:0
29,600 sharesCommon StockSEC:0001193125-26-279719:0
29,600 sharesCommon StockSEC:0001193125-26-279721:0
29,600 sharesCommon StockSEC:0001193125-26-279726:0
29,600 sharesCommon StockSEC:0001193125-26-279728:0
60,000 shares@ US$1.24100.0% of flowCommon StockSEC:0001193125-26-106547:0
51,283 sharesCommon StockSEC:0001193125-26-036281:0
42,083 sharesCommon StockSEC:0001193125-26-036272:0
58,050 sharesCommon StockSEC:0001193125-26-036270:0
54,866 sharesCommon StockSEC:0001193125-26-036269:0
272,983 sharesCommon StockSEC:0001193125-26-036268:0
41,333 sharesCommon StockSEC:0001193125-26-036261:0
29,600 shares0Common StockSEC:0000950170-25-089604:0
29,600 shares0Common StockSEC:0000950170-25-089608:0
29,600 shares0Common StockSEC:0000950170-25-089605:0
29,600 shares0Common StockSEC:0000950170-25-089606:0
29,600 shares0Common StockSEC:0000950170-25-089607:0
29,600 shares0Common StockSEC:0000950170-25-089609:0
44,367 sharesCommon StockSEC:0000950170-25-013849:0
33,333 sharesCommon StockSEC:0000950170-25-013844:0
41,533 sharesCommon StockSEC:0000950170-25-013850:0
173,467 sharesCommon StockSEC:0000950170-25-013846:0
33,333 sharesCommon StockSEC:0000950170-25-013852:0
46,800 sharesCommon StockSEC:0000950170-25-013853:0
25 of 45 declarations
About Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) is a U.S.-based clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, United States. Founded in 2012, Atea focuses on discovering, developing, and commercializing oral antiviral therapeutics for serious viral diseases. The company has built its strategy around proprietary medicinal chemistry, virology expertise, and antiviral drug-development capabilities, targeting pathogens where there remains meaningful unmet medical need. As a late-stage biotech, Atea is not a commercial pharmaceutical company in the traditional sense; its value proposition is driven primarily by clinical execution, regulatory milestones, and the eventual translation of data into a potential approved product.
Atea’s lead program is the fixed-dose combination of bemnifosbuvir and ruzasvir for chronic hepatitis C virus (HCV). Bemnifosbuvir is a nucleotide analog NS5B polymerase inhibitor, while ruzasvir is an NS5A inhibitor. The company is running a global Phase 3 development program consisting of two studies: C-BEYOND in North America and C-FORWARD outside North America. Based on the latest company disclosures, C-BEYOND is fully enrolled with more than 880 patients and topline results are expected in mid-2026, while C-FORWARD is expected to complete enrollment in mid-2026 with topline data anticipated around year-end 2026. If the program is successful, Atea is targeting a U.S. FDA NDA submission in March 2027. For investors, these readouts are the key near-term value inflection points.
Read moreShow less
In 2025 and 2026, Atea also expanded its antiviral pipeline into hepatitis E virus (HEV). In January 2026, the company selected AT-587 as its lead HEV development candidate, with clinical development expected to begin in mid-2026. This is strategically relevant because HEV remains an underserved indication, particularly in immunocompromised patients, and there is currently no approved antiviral therapy. Atea has also reported encouraging preclinical data for AT-587 and related candidates, reinforcing the company’s ambition to build a broader hepatitis-focused antiviral franchise beyond HCV.
Competitively, Atea operates in a field where established HCV treatments from larger pharmaceutical companies set a high bar for efficacy, safety, treatment duration, and convenience. Accordingly, Atea is positioning bemnifosbuvir/ruzasvir as a potentially best-in-class oral regimen with short duration, low drug-drug interaction risk, and practical dosing characteristics. The company’s geographic footprint remains centered in the United States, with its base in Boston and clinical trials spanning North America and other regions. Recent news flow has been dominated by Phase 3 enrollment progress, positive scientific presentations, and the extension of the pipeline into HEV. For French-speaking investors, Atea is a U.S. NASDAQ-listed biotech with a clearly catalyst-driven profile and meaningful clinical upside, but also substantial regulatory and execution risk typical of the sector.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
